China Hypophosphatasia Therapeutics Market Insights and In-Depth Analysis 2023-2028 with Types, Products and Key Players

Report Overview

China Hypophosphatasia Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Hypophosphatasia (HPP) is a rare genetic disorder characterized by the abnormal development of bones and teeth. These abnormalities occur due to defective mineralization such as calcium and phosphorus. The global prevalence of Hypophosphatasia is approximately 1 in 100,000 live births. Hypophosphatasia disease is very harmful to patients of all ages, it is shown that children who showed the first symptoms of hypophosphatasia within 6 months of birth had a high mortality rate, and the mortality rate was 73% at 5 years of age.

Market Drivers

China is a growing market for hypophosphatasia due high demand for disease specific novel treatment, family history of hypophosphatasia, increase in global prevalence rate (1 in 100,000).

There are some restraining factors for growth of hypophosphatasia disease therapeutics market in China such as High cost and less treatment options available.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/139790/

Major Players

Some of the key players in China's hypophosphatasia therapeutics market are Alexion Pharmaceuticals Inc; Novartis AG.

STRENSIQ is an innovative enzyme replacement therapy approved for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP), by Alexion Pharmaceuticals.

Alexion has its presence in China but the drug is not approved in China. Strensiq has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Ministry of Health, Labour and Welfare (MHLW).

Therapies under study- A clinical study conducted by Novartis Pharmaceuticals in Germany: anti-sclerostin antibody BPS804 for the treatment of HPP.

The China Hypophosphatasia Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global China Hypophosphatasia Therapeutics market. This report explores all the key factors affecting the growth of the global China Hypophosphatasia Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On China Hypophosphatasia Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139790/

Market Segmentation

By Therapy:

On the basis of therapy, the China hypophosphatasia therapeutics market can be segmented into enzyme replacement therapy and immunoglobulin therapy. Enzyme replacement therapy using bone-targeting recombinant alkaline phosphatase, or Asfotase alfa (Strensiq), is used as first-line therapy in infants, children, and some adults with HPP. The drug may be used in addition to supportive care to decrease the morbidity associated with the disease.

Supportive treatments for HPP are directed toward specific symptoms and complications. Treatment may require a team of specialists. Paediatricians, orthopaedic surgeons, pain management specialists and other healthcare professionals may be needed for comprehensive treatment.

By Distribution Channels:

On the basis of distribution channels, the China hypophosphatasia therapeutics market can be segmented into retail, online and hospital pharmacies. During the forecast period (2019-2028) the hospital pharmacies segment generates the highest revenue due to most of the major products being prescription products, which are available in hospital pharmacies. Retail and online pharmacies are second largest distribution channels during the forecast period (2019-2028).

By Drug Type:

On the basis of drug type, the China hypophosphatasia therapeutics market can be segmented into Asfotase alfa, non-steroidal anti-inflammatory drugs and thiazide diuretics. Non-steroidal anti-inflammatory drugs (NSAIDs) may help bone and joint pain. NSAIDs require caution and monitoring for side effects (e.g., they can hurt the stomach and kidneys), especially in excess and if used too long. Other supplementary medications such as Vitamin B6 and should avoid the bisphosphonates (These drugs may worsen HPP or cause symptoms in individuals with undiagnosed HPP). Vitamin B6 can help control specific seizures in severely affected infants.

Major Players

Some of the key players in China's hypophosphatasia therapeutics market are Alexion Pharmaceuticals Inc; Novartis AG.

STRENSIQ is an innovative enzyme replacement therapy approved for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP), by Alexion Pharmaceuticals.

Alexion has its presence in China but the drug is not approved in China. Strensiq has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Ministry of Health, Labour and Welfare (MHLW).

Therapies under study- A clinical study conducted by Novartis Pharmaceuticals in Germany: anti-sclerostin antibody BPS804 for the treatment of HPP.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/139790/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global China Hypophosphatasia Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global China Hypophosphatasia Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the China Hypophosphatasia Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the China Hypophosphatasia Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the China Hypophosphatasia Therapeutics
Chapter 4: Presenting the China Hypophosphatasia Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the China Hypophosphatasia Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/139790/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the China Hypophosphatasia Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.